Journal article
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
Abstract
9573
Background: Mucosal melanoma is a rare, highly aggressive form of melanoma with extremely high recurrence rates, despite definitive surgical resection. Median RFS has been reported to be 5.4m, with RFS rates at 1 and 2 years of 10%, and 0%, respectively (Lian B, Si L, Cui C, et al. Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal …
Authors
Kottschade LA; Pond GR; Olszanski AJ; Zakharia Y; Domingo-Musibay E; Hauke RJ; Curti BD; Schober S; Milhem MM; Block MS
Journal
Journal of Clinical Oncology, Vol. 40, No. 16_suppl, pp. 9573–9573
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2022
DOI
10.1200/jco.2022.40.16_suppl.9573
ISSN
0732-183X